Document:

<PAGE>

                                                                   EXHIBIT 10.15

            RESEARCH MATERIAL TRANSFER AND COLLABORATION  AGREEMENT
            -------------------------------------------------------

Lakaro Biopharmaceuticals, Inc., a corporation organized under the laws of the
State of Delaware, USA, with offices at 787 Seventh Avenue, NY, NY  10019 and
216 Jaffa Road, Jerusalem 94383 Israel ("Lakaro"), will provide research
material to *** ("Investigator") for testing on the terms and conditions set
forth in this Research Material Transfer Agreement ("Agreement").

     1.  Lakaro will generate at least two novel peptides based upon a list of
kinases supplied by Investigator to be used as research material as further
described in Section 19, which may be amended during the term of this Agreement
by the written consent of both parties ("Research Materials"). The Research
Materials will be tested in the Areas of Focus as set forth in Section 20
("Research Studies").

     2.  Investigator agrees that any and all Research Materials will be used
under suitable containment conditions solely for in vitro and in vivo laboratory
studies or animal testing, and will not be used in humans.  Investigator
acknowledges that the Research Materials are not intended for human use and,
pursuant to United States Food and Drug Administration regulations, animals
receiving Research Materials and by-products of such animals may not enter the
food chain.  Investigator will comply with all federal, state and local laws and
regulations applicable to the Research Materials.

     3.  The Research Materials are being provided to Investigator pursuant to a
limited license, the sole purpose of which shall be for Investigator to test the
Research Materials to determine their efficacy in the Research Studies, and will
not be used for any commercial purposes.  Investigator further agrees that it
shall not use the Research Materials to analyze the chemical contents of the
Research Materials or make peptide derivatives or peptidomimetics and that
Research Materials will not be transferred or provided to third parties either
within or outside the Investigator's premises without Lakaro's prior written
approval. Investigator acknowledges that Lakaro has informed it that the
Research Materials being provided pursuant to this Agreement are able to
modulate skin biology, including, but not limited to, hair growth and skin
pigmentation.

     4.  Lakaro shall generate the Research Materials within two (2) months
after receiving signed Agreement from the Investigator. Investigator shall have
up to six (6)  months from receipt of the Research Materials to test them
against its in vitro screen.

     5.  Upon reasonable request by Investigator, Lakaro will assist
Investigator in the Research Studies. Investigator shall provide Lakaro with
access to a summary of the results of its testing of the Research Materials in
the Research Studies  within thirty (30) days after the completion of the
Research Studies. Upon completion of the Research Studies, Investigator shall
return to Lakaro or destroy all Research Materials in Investigator's possession.

     6.  The parties will periodically communicate during the conduct of the
Research Studies by conference call and written updates describing the status of
Research Studies.

     7.  Neither party may publish or otherwise disclose data or results
obtained using the data generated by Investigator from the Research Materials
provided (e.g., the results set forth in the summary of  Section 5) without the
other party's prior written approval.

     8.  Unless otherwise expressly provided in writing by Lakaro, no right or
license in or to patents, patent applications, trade secrets or other
intellectual property rights of Lakaro, is granted or implied hereunder, except
for the sole purpose of conducting the studies specifically described herein.

     9.  Investigator acknowledges that the Research Materials are the
confidential property of Lakaro and that in the course of performing the
research studies, both parties recognize that Investigator will and Lakaro may
receive confidential technical and business information of the other party
("Information").  Each party hereby agrees not to use the Information it
receives except for the purpose of conducting the Research Studies and not to
disclose the Information to third parties without the express written permission
of the other party, except for Information:

     (a) that is approved in writing for release by the disclosing party without
restrictions; or

     (b) that the receiving party can demonstrate by written records was
         previously known to the receiving party; or
<PAGE>

     (c) which is now public knowledge, or becomes public knowledge, or becomes
         public knowledge in the future, other than through acts of omissions
         the receiving party in violation of this Section 9;

     (d) which is lawfully obtained by the receiving party from sources
         independent of the disclosing party who have a  lawful right to
         disclose such Information; or

     (e) which is independently developed or acquired by personnel of
         the receiving party who have not had access to, or knowledge of, the
         Information.

In case Information is provided in oral form, the above obligation shall apply
only to the extent such oral Information has been confirmed in writing to the
other party and marked Confidential within forty five (45) days after the date
of oral disclosure. The obligations under the terms of this Section 9 shall
remain in effect for five (5) years after the effective date of this Agreement.
Each party shall be entitled to retain for its legal files a copy of all
Information received under this Agreement for the sole purpose of determining
the scope and effect of its confidentiality obligations hereunder.

     10. Investigator shall pay Lakaro the amount of **** as applicable as
compensation for expenses incurred in the generation of the Research Materials.
Otherwise, each party will bear its own expense for conducting the Research
Studies under this Agreement.

     11. During the term of this Agreement and for up to three(3) months
following the termination of this Agreement, unless mutually extended by the
parties in writing, Investigator shall have an exclusive period in which to
enter into a license and co-development agreement with Lakaro for Research
Materials ("Option Period"). Investigator and Lakaro shall pursue applications
for jointly-held patents where appropriate in connection with the Research
Materials and proprietary materials of Investigator.

     12. Lakaro shall not have the right to publicize the existence of the
relationship reflected in this Agreement without the prior written approval by
Investigator of the proposed publication in each case.

     13. Lakaro acknowledges that Investigator and its affiliates are in the
business of manufacturing and selling cosmetic and pharmaceutical products in
the Areas of Focus that may contain peptides and have an ongoing research and
development effort relating to such products.  In addition, Investigator may
consult with, supply, and jointly develop with third parties such  products.
Nothing contained herein shall be construed to prevent Investigator from
continuing such activities provided only that Investigator shall not reveal to
such third parties, or use for any purpose (other than as permitted by this
Agreement), any Confidential Information of Lakaro covered by this Agreement.

     14. LAKARO PROVIDES NO WARRANTIES FOR THE RESEARCH MATERIALS, EXPRESS
OR IMPLIED, EITHER IN FACT OR BY OPERATION OF LAW, STATUTORY OR OTHERWISE, AND
LAKARO SPECIFICALLY DISCLAIMS ANY IMPLIED WARRANTY OF MERCHANTABILITY, FITNESS
FOR A PARTICULAR PURPOSE OR NON-INFRINGEMENT.

     15. This Agreement shall be governed by, and construed and interpreted in
accordance with, the laws of the State of Israel,  without reference to conflict
of laws principles. Both parties will use their best efforts to settle all
disputes amicably.

     16. No modification to this Agreement, nor any waiver of any rights,
shall be effective unless assented to in writing by the party to be charged and
the waiver of any breach or default shall not constitute a waiver of any other
right hereunder or any subsequent breach or default.  This Agreement constitutes
the entire and exclusive Agreement between the parties hereto with respect to
the subject matter hereof and supersedes and cancels all previous registrations,
agreements, commitments and writings in respect thereof.

     17. Either party may assign this Agreement to a parent, subsidiary,
affiliate or division of that party following written notification of such
assignment to the other party.

     18. Each person signing below and each Party on whose behalf such person
executes this Agreement warrants that he or it, as the case may be, has the
authority to enter this Agreement and perform or cause the party on whose
behalf he has signed to perform the obligations hereunder.

     19. Description and amount of the Research Materials to be provided by
Lakaro :
<PAGE>

     ***

     20. Investigator will test one or more of the Research Materials in the
following Areas of Focus: (i) enhancement of melanogenesis and (ii) the growing
and/or retardation of hair.

     21. This Agreement shall terminate upon the submission to Lakaro of the
summary set forth in Section 5.  The obligations of the parties under Sections
7, 8, 9, 11, 12, 13, 14 and 15 shall survive the termination of this Agreement.

Lakaro Biopharmaceuticals, Inc.    Investigator

By: /s/ Benjamin Corn              By: /s/     ***
    ---------------------------        ----------------------------

Print Name: Benjamin Corn          Print Name: ***

Title: President                   Title: ***

Date: December 12, 1999            Date: December 14, 1999<PAGE>

                                                                   EXHIBIT 10.16

                         MANAGEMENT SERVICES AGREEMENT

THIS MANAGEMENT SERVICES AGREEMENT is made as of the 30th day of November, 1999
by and between Lakaro Biopharmaceuticals, Inc., a Delaware corporation (the
"Sponsor") and B.R.T. Biopharmaceuticals Ltd. (the "Company") an Israeli company
having its registered offices at Sha'arei Ha'ir, 216 Jaffa Street, Jerusalem,
Israel.

WHEREAS the Sponsor is a biopharmaceutical company engaged in the research and
development of biopharmaceutical products for the world market (the "Business");
and

WHEREAS the Sponsor wishes to engage the services of its subsidiary, the
Company, to carry out the services more fully set forth below in connection with
the Business.

NOW, THEREFORE, the parties agree as follows:

1.   Services
     --------

The Company shall, in consultation with the Sponsor:

1.1  supervise and monitor the research and development conducted in Israel in
     connection with the Business;

1.2  advise the Sponsor with respect to the direction of the Sponsor's research
     and product development in connection with the Business; and

1.3  report to the Sponsor on the progress of the research and product
     development being conducted in Israel in connection with the Business; and

1.4  assist in the performance of marketing services on behalf of the Sponsor in
     connection with the Business and any products developed in the Business;

1.5  continue with research and development, which shall include without
     limitation, the conducting of clinical trials; and

1.6  engage the services of advisory firms, consultants, and professionals, as
     it deems necessary, in order to better perform the services enumerated
     above (the "Services") or other services in connection therewith.

2.   Payment
     -------

     In consideration for the Services, the Sponsor will pay the Company during
     the term of this Agreement, a monthly fee equal to the amount of 110% of
     expenses incurred (the "Fee"), to be adjusted annually between the Sponsor
     and the Company, plus Value Added Tax ("VAT") thereon, if payable, at the
     rate applicable at the time of issue by the Company to the Sponsor of a tax
     invoice in respect of the Services.  The Fee shall be paid quarterly in
     advance on the first business day of January, April, July and October in
     each year during the term hereof.
<PAGE>

3.   Effective Period
     ----------------

     This Agreement shall become effective upon its execution, and shall remain
     in effect until either party terminates the Agreement by giving the other
     party ninety (90) days prior written notice of termination.

4.   Relationship of Parties
     -----------------------

     The Company is an independent contractor and is not an agent or employee
     of, and has no authority to bind, the Sponsor by contract or otherwise,
     unless and to the extent expressly authorized in writing by the Board of
     Directors of the Sponsor, whether by grant of power of attorney or
     otherwise.

5.   Confidentiality
     ---------------

     The Sponsor and the Company warrant and undertake that during the term of
     this Agreement and subsequent thereto, it shall maintain confidentiality
     and also be liable for its employees and/or representative and/or persons
     acting on its behalf maintaining absolute confidentiality of all in
     formation, details and data which is in and/or comes to its knowledge
     and/or that of its employees and/or representatives and/or persons acting
     on its behalf directly or indirectly relating to the Services, the Know How
     or any products based on the Know How.  The Sponsor and the Company
     undertake not to convey or disclose (except in connection with the
     fulfillment of its duties under this Agreement) anything in connection with
     the foregoing.  "Confidential Information" shall include, but shall not be
     limited to, confidential or proprietary scientific or technical information
     or data, business plans, trade secrets, or other confidential information
     relating to customers, development programs, costs, marketing, trading,
     investment, sales activities, promotion, credit and financial data,
     manufacturing processes, financing methods, plans or the business and
     affairs of the Sponsor or the Company generally, or of any subsidiary or
     affiliate of the Sponsor or the Company. "Confidential Information" shall
     not include, however, information in the public domain, information
     disclosed to the Sponsor or the Company by a third party entitled to
     disclose it without any obligation of confidentiality, or, information
     already known to the Sponsor or the Company prior to its receipt.

6.   Indemnification.
     ----------------

     The Company agrees to indemnify and hold harmless the Sponsor and its
     respective partners, affiliates, shareholders, directors, officers, agents,
     advisors, representatives, employees, counsel and controlling persons
     within the meaning of the Securities Act of 1933, as amended, (a "Sponsor
     Indemnified Party") from and against any and all direct losses,
     liabilities, claims, damages and expenses whatsoever (and all actions in
     respect thereof) but excluding consequential loss and to reimburse the
     Sponsor Indemnified Party for reasonable legal fees and related expenses as
     incurred (including, but not limited to the costs of giving testimony or
     furnishing documents in response to a subpoena or otherwise, the costs of
     investigating, preparing, pursuing or defending any such action or claim
     whether or not pending or threatened, whether or not resulting in any
     liability, and whether or not the Sponsor or any Sponsor Indemnified Party
     is a party thereto), insofar as such losses, liabilities, claims, damages
     or expenses arise out of, relate to, whether or not resulting in any
     liability, are incurred in connection with or are in any way a result of
     (a) this Agreement, including any modifications or future additions to this
     Agreement, (b)
<PAGE>

     any act by the Company or any Sponsor Indemnified Party taken in connection
     with the services to be provided under this Agreement, (c) the employment
     by the Company of any device, scheme or artifice to defraud, or the
     engaging by the Company in any act, practice or course of business which
     operates or would operate as a fraud or deceit, or any conspiracy with
     respect thereto, in connection with this Agreement; provided, however, that
     the Company will not be liable in any such case if and to the extent that
     any such loss, claim, damage, liability or expense arises out of or is
     based upon the negligence, recklessness or willful misconduct of the
     Sponsor or any Sponsor Indemnified Party.

7.   Amendments: Waivers
     -------------------

     This Agreement may be altered or amended, and any provisions hereof may be
     waived, only upon the written approval of the Sponsor and the Company.

8.   Notices
     -------

     Any notice or other communication given under this Agreement shall be
     deemed to have been given in writing (including telex, telecopy or similar
     teletransmission) addressed as provided below or to the addressee at such
     other address as the addressee shall have specified by notice actually
     received by the addressor), and if either (a) actually delivered in fully
     legible form to such address (evidenced in the case of a telex by receipt
     of the correct answerback) or (b) in the case of a letter, five days shall
     have elapsed after the same shall have been deposited in the post, with
     postage prepaid and registered or certified.

If to the Sponsor, to it at:     c/o Paramount Capital, Inc.
                                 787 Seventh Avenue, 48th floor
                                 New York, New York  10019
                                 Attn: Peter Kash
                                 Tel:  212-554-4340
                                 Fax:  212-554-4355

If to the Company, to it at:     216 Jaffa Road
                                 Sha'arei Ha'ir
                                 Jerusalem, Israel  94383
                                 Attn: Bob Trachtenberg
                                 Tel:  972-2-537-4997
                                 Fax:  972-2-537-5098

9.   Successors
     ----------

     This Agreement shall be binding upon and shall inure to the benefit of the
     parties hereto and their respective heirs, successors and assigns provided,
     however, that neither party may assign this Agreement except to an
     Affiliate that agrees in writing to bound hereby and to assume all of the
     obligations of the assigning party hereunder.  For the purposes hereof, an
     "Affiliate" shall mean any entity that, directly or indirectly through one
     or more intermediaries, controls, or is controlled by, or is under common
     control with, either party hereto.
<PAGE>

10.  Headings
     --------

     The headings in this Agreement are inserted for convenience of reference
     only and shall not be a part of or control or affect the meaning hereof.

11.  Entire Agreement
     ----------------

     This Agreement supersedes any and all oral or written agreements heretofore
     made relating to the subject matter hereof and constitutes the entire
     agreement of the parties relating to the subject matter hereof.

12.  Governing Law
     -------------

     This Agreement shall be governed by and construed in accordance with the
     laws of Israel.

IN WITNESS WHEREOF, each of the undersigned has caused this Agreement to be duly
executed and delivered as an agreement under seal as of the date first above
written.

Lakaro Biopharmaceuticals,  Inc.        B.R.T. Biopharmaceuticals, Ltd.

By: /s/ Bob Trachtenberg                By: /s/ Ira Weinstein
   -----------------------------           ----------------------------
Name: Bob Trachtenberg                  Name: Ira Weinstein
     ---------------------------             --------------------------
Title: Secretary                        Title: CFO
      --------------------------              -------------------------

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00010-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00010-of-00352.parquet"}]]